The Europe biosimilar market was valued at USD 10.13 Billion in 2024, driven by expanding use in treating chronic diseases. With growing adoption across healthcare systems, the market is expected to grow at a CAGR of 12.80%, reaching nearly USD 33.78 Billion by 2034. https://www.expertmarketresearch.com/reports/europe-biosimilar-market